HK1208264A1 - Means and methods applying sflt-1/plgf or endoglin/plgf ratio to rule-out onset of preeclampsia within a certain time period sflt-1/plgf /plgf - Google Patents

Means and methods applying sflt-1/plgf or endoglin/plgf ratio to rule-out onset of preeclampsia within a certain time period sflt-1/plgf /plgf

Info

Publication number
HK1208264A1
HK1208264A1 HK15108816.8A HK15108816A HK1208264A1 HK 1208264 A1 HK1208264 A1 HK 1208264A1 HK 15108816 A HK15108816 A HK 15108816A HK 1208264 A1 HK1208264 A1 HK 1208264A1
Authority
HK
Hong Kong
Prior art keywords
plgf
sflt
endoglin
preeclampsia
rule
Prior art date
Application number
HK15108816.8A
Other languages
English (en)
Chinese (zh)
Inventor
Martin Hund
Maria Schoedl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48741083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1208264(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP12183508.6A external-priority patent/EP2706359A1/fr
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1208264A1 publication Critical patent/HK1208264A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK15108816.8A 2012-06-27 2015-09-10 Means and methods applying sflt-1/plgf or endoglin/plgf ratio to rule-out onset of preeclampsia within a certain time period sflt-1/plgf /plgf HK1208264A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12173886 2012-06-27
EP12183508.6A EP2706359A1 (fr) 2012-09-07 2012-09-07 Supports et procédés pour appliquer le taux sFlt-1 ou endogline/PlGF pour éliminer l'apparition de la toxémie prééclamptique dans une certaine période
PCT/EP2013/063115 WO2014001244A1 (fr) 2012-06-27 2013-06-24 Moyens et méthodes d'utilisation du rapport sflt-1/plgf ou endogline/plgf pour écarter le risque d'apparition d'une pré-éclampsie pendant un certain laps de temps

Publications (1)

Publication Number Publication Date
HK1208264A1 true HK1208264A1 (en) 2016-02-26

Family

ID=48741083

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108816.8A HK1208264A1 (en) 2012-06-27 2015-09-10 Means and methods applying sflt-1/plgf or endoglin/plgf ratio to rule-out onset of preeclampsia within a certain time period sflt-1/plgf /plgf

Country Status (12)

Country Link
US (1) US12085573B2 (fr)
EP (1) EP2867670B1 (fr)
JP (1) JP5937756B2 (fr)
KR (2) KR101996123B1 (fr)
CN (1) CN104412107B (fr)
BR (1) BR112014029233A8 (fr)
CA (1) CA2871878C (fr)
ES (1) ES2681238T3 (fr)
HK (1) HK1208264A1 (fr)
MX (1) MX356775B (fr)
SG (1) SG11201407667UA (fr)
WO (1) WO2014001244A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (fr) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Profil d'expression génétique utilisé comme marqueur de la réceptivité endométriale
US20160025738A1 (en) 2013-03-04 2016-01-28 Iq Products B.V. Prognostic marker to determine the risk for early-onset preeclampsia
ES2685831T3 (es) 2014-01-24 2018-10-11 F. Hoffmann-La Roche Ag Predicción del síndrome de HELLP postparto, de la eclampsia postparto, o de la preeclampsia postparto
CN106662589B (zh) * 2014-03-21 2019-07-30 艾基诺米公司 先兆子痫的早期检测
JP2015207111A (ja) * 2014-04-18 2015-11-19 ソニー株式会社 検査サーバ、検査方法および検査システム
PT3569697T (pt) 2014-06-17 2022-05-02 Asherman Therapy S L Terapia de células estaminais em patologias endometriais
BR112018015532A2 (pt) 2016-02-29 2018-12-26 Hoffmann La Roche métodos para o diagnóstico de pré-eclâmpsia, para avaliar a gravidade da pré-eclâmpsia, e para o monitoramento pré-eclâmpsia, usos de biomarcador, kit adaptado para a realização do método e dispositivo adaptado para diagnosticar se uma paciente sofre de pré-eclâmpsia
NL2016967B1 (en) 2016-06-15 2017-12-21 Iq Products B V Markers and their ratio to determine the risk for early-onset preeclampsia.
JP2020533595A (ja) 2017-09-13 2020-11-19 プロジェニティ， インコーポレイテッド 子癇前症バイオマーカならびに関連するシステムおよび方法
EP3824291A1 (fr) * 2018-07-20 2021-05-26 Roche Diagnostics GmbH Prédiction de prééclampsie fondée sur igfbp -7
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié
CN114200137B (zh) * 2020-09-16 2023-09-01 四川大学 一种以商品化磁珠为内标的比率免疫分析方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916606B2 (en) * 1986-04-30 2005-07-12 Bioveris Corporation Electrochemiluminescent assays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US7141436B2 (en) * 1999-11-03 2006-11-28 Science And Technology Corp. Immunoassay and reagents and kits for performing the same
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6986995B2 (en) * 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
US7435419B2 (en) * 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
BRPI0312818B8 (pt) 2002-07-19 2021-05-25 Beth Israel Deaconess Medical Ct Inc uso de uma medida do nível do polipeptídeo sflt-1 em uma amostra de uma paciente e uso de uma medida dos níveis de pelo menos dois dos peptídeos sflt1, vegf livre ou polipeptídio pigf livre em uma amostra de um paciente usando um métrico
ES2556164T3 (es) * 2003-09-23 2016-01-13 The General Hospital Corporation Cribado de la preeclampsia
US20060067937A1 (en) 2004-09-24 2006-03-30 Karumanchi S A Methods of diagnosing and treating complications of pregnancy
ES2371084T3 (es) 2004-12-21 2011-12-27 Yale University Diagnóstico de la preeclampsia.
US20070111326A1 (en) 2005-11-14 2007-05-17 Abbott Laboratories Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia
JP2010502704A (ja) * 2006-09-07 2010-01-28 メルク エンド カムパニー インコーポレーテッド アルツハイマー病および関連する状態を治療するための二フッ化ピペリジン
CA2676920A1 (fr) * 2007-02-12 2008-08-21 Merck & Co., Inc. Derives de la piperidine
US20090068683A1 (en) * 2007-06-11 2009-03-12 Mayo Foundation For Medical Education And Research Markers for preeclampsia
BRPI0907253A2 (pt) 2008-01-07 2015-07-14 Ortho Clinical Diagnostics Inc Determinação de complexo de sflt-1:fator angiogênico
US9229009B2 (en) 2008-10-31 2016-01-05 Yale University Methods and kits for detecting misfolded proteins
WO2010059952A1 (fr) * 2008-11-20 2010-05-27 Perkinelmer Health Sciences, Inc. Procédé pour déterminer le risque d’éclampsie utilisant les marqueurs pigf-2 et pigf-3
WO2011033034A1 (fr) * 2009-09-17 2011-03-24 Roche Diagnostics Gmbh Batterie de multimarqueurs pour hypertrophie ventriculaire gauche
WO2011080170A1 (fr) * 2009-12-21 2011-07-07 University College Cork, National University Of Ireland, Cork Détection d'un risque de pré-éclampsie
WO2011128357A2 (fr) * 2010-04-13 2011-10-20 Pronota N.V. Biomarqueurs de troubles liés à l'hypertension pendant la grossesse
EP2311865A1 (fr) * 2010-11-19 2011-04-20 F. Hoffmann-La Roche AG Facteur de croissance du placenta pour le diagnostic du cancer
EP2383579A1 (fr) * 2010-12-17 2011-11-02 F. Hoffmann-La Roche AG sFlt-1, troponines cardiaques et peptides natriurétiques pour la reconnaissance de la thérapie avec les inhibiteurs HER-2
EP2490027A1 (fr) * 2011-02-15 2012-08-22 Roche Diagnostics GmbH Moyens et procédés pour le diagnostic de complications de la grossesse basés sur GDF-15 et PlGF/sFlt1

Also Published As

Publication number Publication date
MX2014014463A (es) 2015-02-12
CA2871878C (fr) 2021-08-10
AU2013283540A8 (en) 2014-11-20
ES2681238T3 (es) 2018-09-12
CN104412107A (zh) 2015-03-11
BR112014029233A2 (pt) 2017-06-27
KR20150023063A (ko) 2015-03-04
KR101996123B1 (ko) 2019-07-03
US12085573B2 (en) 2024-09-10
EP2867670B1 (fr) 2018-05-30
BR112014029233A8 (pt) 2019-01-29
CN104412107B (zh) 2018-06-08
KR20160116060A (ko) 2016-10-06
US20150338415A1 (en) 2015-11-26
JP5937756B2 (ja) 2016-06-22
MX356775B (es) 2018-06-13
JP2015525870A (ja) 2015-09-07
EP2867670A1 (fr) 2015-05-06
SG11201407667UA (en) 2015-02-27
CA2871878A1 (fr) 2014-01-03
AU2013283540A1 (en) 2014-11-13
WO2014001244A1 (fr) 2014-01-03

Similar Documents

Publication Publication Date Title
HK1208264A1 (en) Means and methods applying sflt-1/plgf or endoglin/plgf ratio to rule-out onset of preeclampsia within a certain time period sflt-1/plgf /plgf
HK1220279A1 (zh) 預測對精神疾病治療的應答的方法和系統
HK1203855A1 (en) Threads of cross-linked hyaluronic acid and methods of use thereof
HK1206037A1 (en) Human antibodies to gfr3 and methods of use thereof gfr3
EP2991588A4 (fr) Valves prothétiques tissulaires et procédé d'ancrage de celles-ci à des structures cardiovasculaires
EP2850745A4 (fr) Agrégation de ballons pour fournir une largeur de bande demandée à l'avance
EP2910238A4 (fr) Gel d'acide hyaluronique et son procédé de production
HK1214154A1 (zh) 局部類固醇組合物和方法
EP2814132A4 (fr) Système d'accumulateur parallèle et son procédé de commande
GB2508574B (en) Improvements in and relating to the control of ions
HK1212251A1 (en) Topical compositions and methods of use
EP2888590A4 (fr) Anticorps dirigés contre l'olanzapine et leur utilisation
HK1220520A1 (zh) 預測對疼痛治療的應答的方法和系統
EP2906942A4 (fr) Système et procédé d'analyse fondée sur des processeurs
EP2820881A4 (fr) Procédé et système pour la cessation anticipée des émissions en réponse à un accusé de réception de décodage anticipé
EP2821504A4 (fr) Procédé permettant de désigner une maladie en relation avec la quantité de tdp-43 présent dans les cellules
EP2824182A4 (fr) Procédé pour la stimulation de lymphocytes t et son utilisation
EP2870527A4 (fr) Système et procédé associé destinés à faciliter une commande de processus
EP2828649A4 (fr) Systèmes et procédés pour déterminer et contrôler les changements au niveau de l'état de rails
HK1224175A1 (zh) 用於減少痂形成並促進癒合的組合物
EP2922413A4 (fr) Compositions de sel à faible teneur en sodium et procédés de fabrication et d'utilisation
BR112016014485A2 (pt) método de alcançar uma mudança de cor em uma composição de cosmético aplicada a um tegumento humano
HK1206610A1 (en) Fully human antibodies that bind to vegfr2 vegfr2
EP2820561A4 (fr) Procédé et système permettant d'utiliser la neuroscience pour prédire une préférence de consommateur
GB2509033B (en) Composition for coloring skin and method for coloring skin